Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Elosulfase Alfa · Vimizim, BMN-110

Recombinant protein · Protein replacement · developed by Biomarin Pharm

Approved FDA, Feb 2014
BMRN Developer
1 Registered trials

What is Elosulfase Alfa?

Elosulfase alfa is a recombinant form of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase, which is taken up into lysosomes via mannose-6-phosphate receptors and increases the breakdown of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate. It is used in mucopolysaccharidosis type IVA (Morquio A syndrome), a lysosomal storage disorder caused by deficiency of this enzyme.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vimizim, BMN-110
Drug type
Recombinant protein
Mechanism
Protein replacement
Pathways
lysosomal glycosaminoglycan catabolism, mannose-6-phosphate receptor-mediated lysosomal uptake
Therapy area
Metabolic
Developer
Biomarin Pharm (BMRN)
FDA status
Approved as Vimizim (February 14, 2014), BLA125460 · FDA label
UNII
ODJ69JZG85

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 30, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03204370 N/A Mucopolysaccharidosis IV A Completed BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mucopolysaccharidosis IV A

More from Biomarin Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Elosulfase Alfa

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.